JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $1150
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Chris Schott maintains an Overweight rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raises the price target from $1050 to $1150.
June 17, 2024 | 2:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Chris Schott maintains an Overweight rating on Regeneron Pharmaceuticals and raises the price target from $1050 to $1150.
The increase in the price target from $1050 to $1150 by a reputable analyst at JP Morgan is a positive signal for investors. The Overweight rating suggests that the stock is expected to outperform the market, likely leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100